Biomedical perspective on onabotulinumtoxinA: efficacy and clinical management in chronic migraine treatment
DOI:
https://doi.org/10.33448/rsd-v15i5.51006Keywords:
Biomedicine, Migraine, Prophylaxis, Botulinum Toxin Type A.Abstract
Chronic migraine is a debilitating neurological pathology characterized by the sensitization of the trigeminovascular system, affecting the functionality and quality of life of a significant portion of the global population. This study analyzed the efficacy of onabotulinumtoxinA (botulinum toxin type A) in the prophylactic treatment of this condition, emphasizing the strategic role of the biomedical professional. An integrative literature review (2016-2026) was conducted using PubMed, SciELO, VHL, and Cochrane databases, selecting studies that followed the PREEMPT protocol. The results demonstrate that the neurotoxin acts via the cleavage of the SNAP-25 protein, inhibiting the exocytosis of nociceptive neuropeptides (such as CGRP) and stabilizing the pain threshold. In this context, the role of biomedicine proves to be fundamental, as therapeutic efficacy directly depends on an unparalleled mastery of craniocervical topographic anatomy for the precise mapping of sensory endings. The biomedical professional operates in advanced clinical management, applying pharmacodynamic reasoning for the safe execution of the protocol and focal dosage adjustments (follow-the-pain). It is concluded that the technical precision and anatomical rigor inherent to biomedical practice are decisive factors in reducing morbidity, mitigating adverse effects, and improving the quality of life for patient’s refractory to conventional treatments.
References
Ahmed, F., Gaul, C., García-Moncó, J. C., Sommer, K., Martelletti, P., & REPOSE Principal Investigators (2019). An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. The journal of headache and pain, 20(1), 26. https://doi.org/10.1186/s10194-019-0976-1
Ahmed, F., Gaul, C., Kollewe, K., Singh, R. C., & Sommer, K. (2025). Real-World Safety and Efficacy of 156 U - 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study. BMC neurology, 25(1), 197. https://doi.org/10.1186/s12883-025-04087-7
Ailani, J., Burch, R. C., Robbins, M. S., & Board of Directors of the American Headache Society (2021). The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache, 61(7), 1021–1039. https://doi.org/10.1111/head.14153
Amaral, G. C. S. do, Faria, M. R. de, & Arruda, J. T. (2026). Toxina botulínica tipo A no manejo da enxaqueca crônica: da modulação nociceptiva a eficácia clínica. Caderno Pedagógico, 23(3), e23380. https://doi.org/10.54033/cadpedv23n3-042
Ashina, M., Hansen, J. M., Do, T. P., Melo-Carrillo, A., Burstein, R., & Moskowitz, M. A. (2019). Migraine and the trigeminovascular system-40 years and counting. The Lancet. Neurology, 18(8), 795–804. https://doi.org/10.1016/S1474-4422(19)30185-1
Ashina, M., Katsarava, Z., Do, T. P., Buse, D. C., Pozo-Rosich, P., Özge, A., Krymchantowski, A. V., Lebedeva, E. R., Ravishankar, K., Yu, S., Sacco, S., Ashina, S., Younis, S., Steiner, T. J., & Lipton, R. B. (2021). Migraine: epidemiology and systems of care. Lancet (London, England), 397(10283), 1485–1495. https://doi.org/10.1016/S0140-6736(20)32160-7
Ashina, S., Terwindt, G. M., Steiner, T. J., Lee, M. J., Porreca, F., Tassorelli, C., Schwedt, T. J., Jensen, R. H., Diener, H. C., & Lipton, R. B. (2023). Medication overuse headache. Nature reviews. Disease primers, 9(1), 5. https://doi.org/10.1038/s41572-022-00415-0
Barkataky, N., Ali, A., Lihite, R. J., Das, R., Barua, A. R., Ali, A. S., Borah, N. C., Barman, A., & Gang, S. (2026). Assessment of Quality of Life of Patients with Chronic Migraine on OnabotulinumtoxinA Therapy-A Study Performed at a Super Specialty Tertiary Hospital in Northeast India. Neurology India, 74(2), 256–260. https://doi.org/10.4103/neurol-india.Neurol-India-D-25-00249
Batty, A. J., Hansen, R. N., Bloudek, L. M., Varon, S. F., Hayward, E. J., Pennington, B. W., Lipton, R. B., & Sullivan, S. D. (2013). The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. Journal of medical economics, 16(7), 877–887. https://doi.org/10.3111/13696998.2013.802694
Bendtsen, L., Sacco, S., Ashina, M., Mitsikostas, D., Ahmed, F., Pozo-Rosich, P., & Martelletti, P. (2018). Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. The journal of headache and pain, 19(1), 91. https://doi.org/10.1186/s10194-018-0921-8
Blumenfeld, A. M., Charleston, L., 4th, Kuruvilla, D., Savage-Edwards, B., Lipton, R. B., Singh, R., Jacob, P., Lawrence, N. A., Wang, C., & O'Brien, H. L. (2025). OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trial. Headache, 10.1111/head.70007. Advance online publication. https://doi.org/10.1111/head.70007
Blumenfeld, A. M., Frishberg, B. M., Schim, J. D., Iannone, A., Schneider, G., Yedigarova, L., & Manack Adams, A. (2021). Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. Pain and therapy, 10(2), 809–826. https://doi.org/10.1007/s40122-021-00264-x
Blumenfeld, A. M., Rhyne, C., Martinez, K., Patel, A., Becker Ifantides, K., Singh, R., Yushmanova, I., Battucci, S., Schwartz, M., & Forde, G. (2026). Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Chronic Migraine and Concomitant Therapeutic Indications. Pain and therapy, 15(2), 535–553. https://doi.org/10.1007/s40122-026-00816-z
Blumenfeld, A. M., Silberstein, S. D., Dodick, D. W., Aurora, S. K., Brin, M. F., & Binder, W. J. (2017). Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. Headache, 57(5), 766–777. https://doi.org/10.1111/head.13074
Blumenfeld, A. M., Stark, R. J., Freeman, M. C., Orejudos, A., & Manack Adams, A. (2018). Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The journal of headache and pain, 19(1), 13. https://doi.org/10.1186/s10194-018-0840-8
Brin, M. F., & Burstein, R. (2023). Botox (onabotulinumtoxinA) mechanism of action. Medicine, 102(S1), e32372. https://doi.org/10.1097/MD.0000000000032372
Ceccardi, G., Schiano di Cola, F., Caratozzolo, S., Di Pasquale, M., Bolchini, M., Padovani, A., & Rao, R. (2023). Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine. Toxins, 15(12), 677. https://doi.org/10.3390/toxins15120677
Chamani, G., Jasim, H., Minston, A., Dias, M. F., Poluha, R. L., Gonçalves, D. A. G., Christidis, M., Al-Moraissi, E. A., Christidis, N., De la Torre Canales, G., & Ernberg, M. (2026). Botulinum Toxin Type A for the Prevention of Migraines: An Umbrella Review of Systematic Reviews. Toxins, 18(1), 33. https://doi.org/10.3390/toxins18010033
Corasaniti, M. T., Bagetta, G., Nicotera, P., Tarsitano, A., Tonin, P., Sandrini, G., Lawrence, G. W., & Scuteri, D. (2023). Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Toxins, 15(5), 332. https://doi.org/10.3390/toxins15050332
Diener, H. C., Dodick, D. W., Aurora, S. K., Turkel, C. C., DeGryse, R. E., Lipton, R. B., Silberstein, S. D., Brin, M. F., & PREEMPT 2 Chronic Migraine Study Group (2010). OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia : an international journal of headache, 30(7), 804–814. https://doi.org/10.1177/0333102410364677
Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H. C., Brin, M. F., & PREEMPT Chronic Migraine Study Group (2010). OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache, 50(6), 921–936. https://doi.org/10.1111/j.1526-4610.2010.01678.x
Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H. C., Brin, M. F., & PREEMPT Chronic Migraine Study Group (2010). OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache, 50(6), 921–936. https://doi.org/10.1111/j.1526-4610.2010.01678.x
Domitrz, I., Sławek, J., Słowik, A., Boczarska-Jedynak, M., Stępień, A., Rejdak, K., Gierczyński, J., & Rożniecki, J. (2022). Onabotulinumtoxin A (ONA-BoNT/A) in the treatment of chronic migraine. Neurologia i neurochirurgia polska, 56(1), 39–47. https://doi.org/10.5603/PJNNS.a2021.0061
Edvinsson L. (2017). The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. Headache, 57 Suppl 2, 47–55. https://doi.org/10.1111/head.13081
GBD 2021 Causes of Death Collaborators (2024). Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet (London, England), 403(10440), 2100–2132. https://doi.org/10.1016/S0140-6736(24)00367-2
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J., Ives, N., Clarke, C. E., & Sinclair, A. (2018). Botulinum toxins for the prevention of migraine in adults. The Cochrane database of systematic reviews, 6(6), CD011616. https://doi.org/10.1002/14651858.CD011616.pub2
Kowacs, F., Roesler, C. A. P., Piovesan, É. J., Sarmento, E. M., Campos, H. C., Maciel, J. A., Calia, L. C., Barea, L. M., Ciciarelli, M. C., Valença, M. M., Costa, M. E. N. M., Peres, M. F. P., Kowacs, P. A., Rocha-Filho, P. A. S., Silva-Néto, R. P., Villa, T. R., & Jurno, M. E. (2019). Consensus of the Brazilian Headache Society on the treatment of chronic migraine. Arquivos De Neuro-psiquiatria, 77(7), 509–520. https://doi.org/10.1590/0004-282X20190078 Erratum. (2019). Erratum. Arquivos De Neuro-psiquiatria, 77(10), 758–758. https://doi.org/10.1590/0004-282x20190078err
Lang, H., Peng, C., Wu, K., Chen, X., Jiang, X., He, L., & Chen, N. (2024). Efficacy and safety of onabotulinumtoxinA in the treatment of medication overuse headache: a systematic review. Frontiers in neurology, 15, 1453183. https://doi.org/10.3389/fneur.2024.1453183
Navarro-Pérez MP, González-Quintanilla V, Muñoz-Vendrell A, Madrigal E, Alpuente A, Latorre G, Molina F, Monzón MJ, Medrano V, García-Azorín D, González-Oria C, Gago-Veiga A, Velasco F, Beltrán I, Morollón N, Viguera J, Casas-Limón J, Rodríguez-Vico J, Cuadrado E, Irimia P, Iglesias F, Guerrero-Peral ÁL, Belvís R, Pozo-Rosich P, Pascual J and Santos-Lasaosa S (2024) Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study. Front. Neurol. 15:1417831. doi: https://doi.org/10.3389/fneur.2024.1417831
Pereira, A. S. et al. (2018). Metodologia da pesquisa cientifica. [Free ebook]. Santa Maria. Editora da UFSM.
Pozo-Rosich, P., Alpuente, A., Silberstein, S. D., & Burstein, R. (2024). Insights from 25 years of onabotulinumtoxinA in migraine - mechanisms and management. Nature reviews. Neurology, 20(9), 555–568. https://doi.org/10.1038/s41582-024-01002-5
Risemberg, R. I. C. et al. (2026). A importância da metodologia científica no desenvolvimento de artigos científicos. E-Acadêmica, 7(1), e0171675. https://eacademica.org/eacademica/article/view/675.
Robblee J, Minen MT, Friedman BW, Cortel-LeBlanc MA, Cortel-LeBlanc A, Orr SL. (2026). 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. Headache, 66(1):53-76. https://doi.org/10.1111/head.70016
Rossetto, O., Pirazzini, M., & Montecucco, C. (2014). Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature reviews. Microbiology, 12(8), 535–549. https://doi.org/10.1038/nrmicro3295
Rothrock, J. F., Adams, A. M., Lipton, R. B., Silberstein, S. D., Jo, E., Zhao, X., Blumenfeld, A. M., & FORWARD Study investigative group (2019). FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. Headache, 59(10), 1700–1713. https://doi.org/10.1111/head.13653
Rummel A. (2013). Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Current topics in microbiology and immunology, 364, 61–90. https://doi.org/10.1007/978-3-642-33570-9_4
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of Business Research. 104, 333-9. https://doi.org/10.1016/j.jbusres.2019.07.039.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Rosa Maria de Souza, Gabriel Henrique Avelino de Sá, Risalva Alves dos Santos Andrade, Eberte Silva Melo, Sérgio Willy Xavier da Costa, Jalsi Tacon Arruda
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
